Floatz logo

Incagn02390

RCC

Incyte CorporationPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the RCC cohort.

Asset / SponsorPhaseRating
mk-3795
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1CC
SPX-303
SparX Biotech(Jiangsu) Co., Ltd.
Phase 1CC

Same molecule, other indications

Incagn02390 is also rated in:

melanomaDormant
CCC
Indicative ·
53 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
MSIDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →